{"id":"NCT00783692","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2012-03","completion":"2012-05","firstPosted":"2008-11-03","resultsPosted":"2014-07-21","lastUpdate":"2014-07-21"},"enrollment":1116,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"vedolizumab","otherNames":["Entyvio","MLN0002","MLN02","LDP-02"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vedolizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.","primaryOutcome":{"measure":"Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6","timeFrame":"Week 6","effectByArm":[{"arm":"Placebo","deltaMin":6.8,"sd":null},{"arm":"DB Vedolizumab","deltaMin":14.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0206"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":114,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["33200296","32635680","30615117","30203005","29857145","29471381","26893500","25996351","23964933"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":148},"commonTop":["Arthralgia","Headache","Pyrexia","Crohn's disease","Nasopharyngitis"]}}